Skip to main content

Table 1 Baseline patient, disease, and transplant characteristics

From: Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia

 

MMUD (N = 280)

CBT (N = 902)

p value

Follow-up (reverse KM, months)

Median (IQR)

19.1 (11.4–36.7)

46.8 (22.6–72.6)

< 0.001

Patient age (years)

   

Median (min–max) [IQR]

52.1 (18.2–75.6) [39.9–61.2]

50.5 (18.1–73.2) [38.4–60.3]

0.087

Year transplant

Median (min–max) [IQR]

2017 (2010–2019)

2013 (2010–2019)

< 0.001

Cytogenetics risk groupa

   

Good risk

18 (6.4%)

50 (5.5%)

0.001

Intermediate risk

148 (52.9%)

366 (40.6%)

 

Adverse risk

40 (14.3%)

144 (16%)

 

Unknown risk

74 (26.4%)

342 (37.9%)

 

Disease status at transplantation

CR1

179 (63.9%)

522 (57.9%)

0.023

CR2 +

49 (17.5%)

230 (25.5%)

 

Advanced

52 (18.6%)

150 (16.6%)

 

Patient gender

   

Male

163 (58.2%)

430 (47.7%)

0.002

Donor gender

   

Male

187 (68.2%)

421 (50%)

< 0.001

Missing

6

60

 

Female donor to male recipient

 

35 (12.7%)

194 (22.2%)

< 0.001

Missing

5

29

 

HCT-CI

0

125 (59%)

294 (57.3%)

0.073

1 or 2

32 (15.1%)

112 (21.8%)

 

≥ 3

55 (25.9%)

107 (20.9%)

 

Missing

68

389

 

KPS score

≥ 90

76 (27.1%)

210 (23.3%)

0.19

Patient CMV serostatus: positive

Positive

201 (73.6%)

587 (66.9%)

0.036

Missing

7

24

 

Donor CMV serostatus: positive

Positive

127 (45.8%)

260 (35.2%)

0.002

Missing

3

163

 

Graft source

 

BM—19 (6.8%)

Single unit—408 (45.2%)

 
 

PBSC—261 (93.2%)

Double unit—494 (54.8%)

 

Conditioning regimen intensity

MAC

141 (50.4%)

416 (46.1%)

0.21

RIC

139 (49.6%)

486 (53.9%)

 

Type of conditioning regimen

BuCy

14 (5%)

23 (2.5%)

< 0.001

BuFlu

116 (41.4%)

14 (1.6%)

 

TBF

45 (16.1%)

263 (29.2%)

 

TBI-based

38 (13.6%)

522 (57.9%)

 

Other

67 (23.9%)

80 (8.9%)

 

GVHD prophylaxisb

csa + mmf

111 (39.6%)

638 (70.7%)

 

tacro + mmf

51 (18.2%)

22 (2.4%)

 

csa + mtx

10 (3.6%)

35 (3.9%)

 

csa

34 (12.1%)

183 (20.3%)

 

tacro

24 (8.6%)

2 (0.2%)

 

siro + mmf

14 (5%)

8 (0.9%)

 

other

36 (12.9%)

14 (1.6%)

 
  1. CMV cytomegalovirus; GVHD graft-versus-host disease, KPS Karnofsky performance status, HCT-CI hematopoietic cell transplantation comorbidity index, KM Kaplan–Meier, IQR interquartile rage, BM bone marrow, PBSC peripheral blood stem cell, MAC myeloablative conditioning, RIC reduced-intensity conditioning, BuCy busulfan cyclophosphamide, BuFu busulfan, fludarabine, TBF thiotepa, busulfan, fludarabine, TBI total body irradiation, CSA cyclosporine, mtx methotrexate, mmf mycophenolate mofetil, tacro tacrolimus, siro sirolimus
  2. aPer UK MRC criteria
  3. bAll MMUD patients received PTCy